View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2020updated 07 Sep 2020 9:59am

Novavax secures CEPI funding for Covid-19 vaccine

Novavax has received initial funding of $4m from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a Covid-19 vaccine.


Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Novavax has received initial funding of $4m from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a Covid-19 vaccine.

The company is in discussions with CEPI for additional funds to support development through to Phase I.

Last month, the company started testing its recombinant nanoparticle vaccine candidates for coronavirus in animal models.

The candidates produce antigens derived from the coronavirus spike (S) protein. Novavax is planning to use its Matrix-M adjuvant with its Covid-19 vaccine candidates to boost immune responses.

The company expects the preclinical findings to help determine an optimal candidate for human studies, with a clinical trial anticipated to begin in May or June.

Novavax president and CEO Stanley Erck said: “This first stage of funding from CEPI is critical to enable the ongoing development of our Covid-19 vaccine candidates.

“We commend CEPI for its role as a vital partner to bridge the funding gap for innovative biotech companies like Novavax, which have robust vaccine technology platforms. Novavax is working tirelessly to create a vaccine against this growing epidemic.”

CEPI is funding multiple research projects aimed at developing a vaccine against Covid-19 disease.

CEPI CEO Richard Hatchett said: “The current crisis shows that we cannot prevent all infectious diseases from emerging. But we can and must double down on developing vaccines.

“CEPI has moved quickly and urgently to coordinate with global health authorities and vaccine-development partners. CEPI is pleased to be partnering with Novavax to rapidly develop a potential vaccine candidate against the global threat posed by Covid-19.”

In a separate development, Novavax signed an agreement with Emergent BioSolutions for contract development and manufacturing (CDMO) services.

As part of the agreement, Emergent will manufacture Novavax’s Covid-19 experimental vaccine candidate for use in the Phase I trial.

Also, the deal provides access to Emergent’s rapid deployment capabilities and expertise for Novavax to generate vaccine product for stockpiling.

Emergent will produce drug substance at its Bayview facility and drug product at its Camden facility in the US.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology